S36 Cushing Disease: An Update on Pathogenesis, Diagnosis, and Medical Treatment

Program: Symposia
Clinical/Translational Session
Saturday, April 2, 2016: 4:45 PM-6:15 PM
BR East (BCEC)
Chair:
Beverly M.K. Biller, MD, FACP, Massachusetts General Hospital/Harvard Medical School, Boston, MA

Disclosures:
BMKB: Consultant, Cortendo, Principal Investigator, Cortendo, Consultant, HRA Pharma, Consultant, Novartis Pharmaceuticals, Principal Investigator, Novartis Pharmaceuticals.
4:45 PM
G√ľnter K. Stalla, MD, Department of Internal Medicine, Endocrinology and Clinical Chemistry, Max Planck Institute of Psychiatry, Munich, Germany
Nothing to Disclose: GKS
5:15 PM
Hershel Raff, PhD, Aurora St. Luke's Medical Center, Med College of Wisconsin, Milwaukee, WI
Disclosures:
HR: Consultant, Corcept.
5:45 PM
Maria Fleseriu, MD, FACE, Departments of Medicine and Neurological Surgery, Northwest Pituitary Center, Oregon Health & Science University, Portland, OR
Disclosures:
MF: Principal Investigator, Chiasma, Principal Investigator, Consulting fee, Principal Investigator, Pfizer, Inc., Ad Hoc Consultant, Novartis Pharmaceuticals, Principal Investigator, Ipsen, Ad Hoc Consultant, Chiasma, Principal Investigator, Cortendo, Ad Hoc Consultant, Cortendo.
See more of: Symposia

 

The Endocrine Society would like to thank the following organizations for their support: AbbVie Inc.; Bayer HealthCare Pharmaceuticals Inc.; Boehringer Ingelheim Pharmaceuticals, Inc.; Chiasma, Inc.; Corcept Therapeutics Incorporated; Eisai, Inc.; Ethicon Endo-Surgery, Inc.; Genzyme, a Sanofi company, Ipsen Biopharmaceuticals, Inc.; Leona M. and Harry B. Helmsley Charitable Trust; Lilly USA, LLC; Medtronic Diabetes; Merck & Co., Inc.; Novartis Pharmaceuticals Corporation; Novo Nordisk Inc.; Pfizer, Inc.; Shire